Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CircRNA Synthesis Market: Enzymatic Circularization Method Demand, Custom Synthesis Service Growth, and GMP Scale-Up Manufacturing Adoption to Drive Strong Market Expansion Through 2036

The global CircRNA Synthesis Market was valued at USD 192.5 million in 2025 and is projected to expand at a strong CAGR of 16.2%, reaching approximately USD 864.0 million by 2036. This growth trajectory is being driven by sustained demand for enzymatic circularization synthesis methods, growing reliance on custom circRNA synthesis services, and continued investment in GMP-compliant scale-up manufacturing capacity. The market comprises reagents and kits, specialized instruments, and custom synthesis services spanning sequence design through circularization, purification, and characterization, supporting biopharmaceutical developers pursuing circular RNA therapeutic and vaccine applications.

The market’s strong 16.2% CAGR reflects growing biopharmaceutical investment in specialized manufacturing infrastructure supporting circular RNA’s distinctive closed-loop molecular architecture, generating structured demand from RNA therapeutic developers well above discretionary life sciences tools demand growth. Enzymatic synthesis methods, including ribozyme-mediated and RNA ligase-mediated circularization alongside in vitro transcription combined with circularization, continue to represent the leading synthesis approaches, while custom synthesis services spanning construct design through GMP-scale production continue to represent an increasingly important service category. Coverage extending across multiple product and service categories, synthesis methods, and construct types underscores the breadth of manufacturing infrastructure now supporting this rapidly expanding RNA synthesis category.

Executive Snapshot

How does enzymatic circularization method demand drive the circRNA synthesis market?
Biopharmaceutical developers continue to rely on ribozyme-mediated and RNA ligase-mediated circularization methods alongside in vitro transcription combined with circularization, establishing these enzymatic approaches as the leading synthesis technology for the category. As enzymatic circularization technology continues to mature, procurement associated with this synthesis method is expected to remain a leading category through the forecast period.

What role does custom synthesis service growth play in market expansion?
Biopharmaceutical developers continue to rely on custom circRNA synthesis services spanning sequence and construct design, circularization, purification, and characterization and quality control, sustaining structured demand from developers pursuing this specialized manufacturing expertise for this technically demanding RNA construct class.

How does GMP scale-up manufacturing adoption sustain market growth?
Contract manufacturers and biopharmaceutical developers continue to invest in GMP-compliant scale-up synthesis capacity for circular RNA production, sustaining structured demand from developers pursuing this manufacturing capability as circRNA candidates progress from research-scale production toward clinical and commercial-scale manufacturing requirements.

What is driving demand for circRNA synthesis in engineered synthetic construct applications?
Developers pursuing engineered and synthetic circRNA constructs continue to extend circular RNA synthesis technology beyond naturally derived and exogenous circRNA approaches, generating incremental demand among clinical-stage biopharmaceutical developers pursuing these differentiated protein-coding and regulatory circRNA architectures.

How does chemical and synthetic scaffold-based synthesis method demand sustain the market?
Biopharmaceutical developers continue to explore chemical and synthetic scaffold-based circularization methods as emerging alternatives to conventional enzymatic approaches, sustaining structured demand from developers pursuing these differentiated synthesis technologies.

Which circRNA synthesis market segments are growing fastest?
The fastest-growing segments include GMP scale-up synthesis services, engineered and synthetic circRNA constructs, chemical and synthetic scaffold-based synthesis methods, and characterization and quality control services supporting clinical and commercial manufacturing.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: CircRNA Synthesis Market

  • Enzymatic synthesis sustaining the leading share of current circRNA production methodology: Ribozyme-mediated and RNA ligase-mediated circularization continue to represent the most established and widely adopted synthesis approaches.
  • Custom synthesis services sustaining the leading share of current market activity across the manufacturing value chain: Construct design, circularization, and purification services continue to represent a substantial share of overall circRNA synthesis market spending.
  • Therapeutic circRNA sustaining the dominant construct application category across current manufacturing demand: This application continues to anchor the substantial majority of current circRNA synthesis market activity given growing therapeutic pipeline development.
  • GMP-compliant scale-up synthesis sustaining structured demand growth as candidates progress toward clinical and commercial manufacturing: This manufacturing capability continues to attract structured investment as the circRNA therapeutic pipeline matures beyond early research applications.
  • Engineered and synthetic circRNA constructs sustaining structured demand growth as an increasingly important construct category: These differentiated architectures continue to broaden the category’s overall addressable manufacturing technology market.
  • Characterization and quality control services sustaining structured demand growth supporting regulatory compliance: These services continue to attract structured investment as developers pursue rigorous analytical infrastructure for clinical-stage and commercial products.

Market Segmentation: CircRNA Synthesis Market

By Product & Service
  • Reagents & Kits
  • Instruments
  • Synthesis Services
By Synthesis Method
  • Enzymatic Synthesis
  • In Vitro Transcription (IVT) + Circularization
  • Chemical / Synthetic Scaffold-Based Methods
  • Other Emerging Synthesis Methods
By CircRNA Type
  • Exogenous CircRNA
  • Endogenous / Naturally Derived CircRNA
  • Therapeutic CircRNA
  • Regulatory / Non-Coding CircRNA
  • Protein-Coding CircRNA
  • Engineered / Synthetic CircRNA
By Grade
  • Research Grade
  • Preclinical Grade
  • Clinical / GMP Grade
  • Commercial Grade
By Application
  • Therapeutics Development
    • Oncology
    • Infectious Diseases
    • Genetic / Rare Diseases
    • Cardiovascular Diseases
    • Other Therapeutic Areas
  • Vaccine Development
  • Drug Discovery
  • Gene & Cell Therapy Development
  • Diagnostics & Biomarker Discovery
  • Academic & Basic Research
  • Other Applications
By End User
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Academic & Research Institutes
  • Diagnostic Laboratories
  • Government / Public Research Organizations
  • Others
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: CircRNA Synthesis Market

  1. Sustained biopharmaceutical demand for enzymatic circularization technology driving continued manufacturing investment: This established synthesis methodology continues to support structured demand above the discretionary life sciences tools baseline.
  2. Growing reliance on custom synthesis services supporting specialized circRNA manufacturing expertise: This service category continues to attract structured investment as developers pursue reliable, high-quality construct production.
  3. Continued investment in GMP scale-up capacity supporting clinical and commercial manufacturing readiness: This manufacturing capability continues to attract structured investment as circular RNA candidates progress through clinical development.
  4. Sustained technology innovation in engineered and synthetic circRNA constructs supporting pipeline diversification: These differentiated architectures continue to attract structured developer investment pursuing improved therapeutic performance.
  5. Growing quality control and characterization infrastructure investment supporting regulatory compliance: These capabilities continue to attract structured investment as developers pursue rigorous analytical standards for clinical-stage products.
  6. Maturing circular RNA therapeutic pipeline supporting continued manufacturing market expansion: Growing clinical validation of circRNA therapeutic and vaccine candidates continues to focus industry attention on the category’s manufacturing infrastructure needs.

Regional Outlook: CircRNA Synthesis Market

  • North America: The United States accounts for the largest share of regional demand, supported by extensive biopharmaceutical developer activity and leading contract manufacturing infrastructure for RNA-based products.
  • Europe: Germany, the United Kingdom, and Switzerland anchor regional demand, supported by growing specialized RNA manufacturing capacity and consistent biopharmaceutical developer activity.
  • Asia-Pacific: China, Japan, and South Korea represent some of the fastest-growing regional markets as regional biopharmaceutical developers and contract manufacturers expand circular RNA synthesis capacity.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as biopharmaceutical developers begin to explore circular RNA synthesis service partnerships.

Competitive Landscape: CircRNA Synthesis Market

Key Players
Orna Therapeutics, Inc., Laronde, Inc., Sail Biomedicines, Inc., Circio Holding ASA, Thermo Fisher Scientific Inc., New England Biolabs, Inc., TriLink BioTechnologies (Maravai LifeSciences), Aldevron, LLC (Danaher Corporation), Flagship Pioneering-Backed RNA Platforms, CirCode AB

  • Orna Therapeutics, Inc. [March 2026] — confirmed continued expansion of its circular RNA manufacturing platform, with the company noting sustained biopharmaceutical developer interest in its proprietary circularization technology.
  • Laronde, Inc. [December 2025] — reported continued investment in its endless RNA manufacturing platform, with the company noting sustained interest in extending circular RNA technology across multiple therapeutic applications.
  • TriLink BioTechnologies (Maravai LifeSciences) [September 2025] — confirmed continued expansion of its circular RNA synthesis service offerings, with the company reporting structured interest from developers pursuing GMP-scale production capacity.

Consultant POV

The CircRNA Synthesis Market’s strong 16.2% CAGR from USD 192.5 million in 2025 toward approximately USD 864.0 million by 2036 is anchored in sustained enzymatic circularization method demand, growing custom synthesis service activity, and continued GMP scale-up manufacturing adoption. Sustained infrastructure and manufacturing investment from companies including Orna Therapeutics, Inc., Laronde, Inc., and TriLink BioTechnologies (Maravai LifeSciences) confirms the CircRNA Synthesis Market will sustain strong growth through 2036.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report